PACTR202402700796695Other3 期
Acceptability and Feasibility of long-acting INjectable ART in Adolescents and Young Adults.
Desmond Tutu Health Foundation0 个研究点目标入组 200 人开始时间: 2023年5月3日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- Other
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 13 Year(s) 至 18 Year(s)（—）
- 性别
- All
入选标准
- •Known HIV-1 positive.
- •Aged 12 - 24 years inclusive.
- •Clinically well (no current HIV-related illnesses).
- •Weight = 35 kg.
- •Willing to switch to a long-acting injectable ART regimen for a 48-week period.
- •Be virally suppressed (<50 copies/ml) at time of switch.
- •Willing to be followed by the study team for 96 weeks after switch.
- •Able to understand and comply with protocol requirements and sign full informed assent / consent.
- •For women and adolescents of childbearing potential, be willing to use effective contraception for the duration of the study (including the post-trial access period and the 48-week follow-up phase). This includes the use of oral or injectable hormonal contraceptives, a contraceptive implant or an intrauterine device (IUD).
- •In addition, for cohort 1 (n=75):
- •Currently receiving standard of care first-line ART.
- •Suppressed viral load at the last 2 SOC measurements, with the most recent viral load drawn within 12 months of screening date (so indicating >1 year of viral suppression). Note: SOC viral load are drawn every 12 months.
- •No evidence of recent poor adherence (e.g. missed clinic visits or missed pharmacy collection).
- •In addition, for cohort 2 (n=50):
- •Currently receiving standard of care first-line ART.
- •Most recent clinic viral load =50 copies/ml (but previous viral load suppressed) OR other evidence of poor adherence in past year (e.g. a missed pharmacy collection or missed clinic visits).
- •Willing to receive enhanced adherence support prior to switch.
- •In addition, for cohort 3 (n=75)
- •ART-naïve, by self-report.
- •About to commence SOC first-line ART;
排除标准
- •Adolescent or caregiver unwilling to participate in an ART switch study.
- •History of hypersensitivity to any of the study drugs or their components.
- •Known HIV-1 resistance to any of the study ART drug groups (NNRTIs or INSTIs).
- •History of seizures or people at risk of seizures.
- •Abnormal liver function (>2.5 x ULN ALT or AST).
- •Evidence of Hepatitis B infection (positive Hep B surface antigen or anti-core AB).
- •Severe hepatic impairment and those with advanced hepatitis C, or those expected to need the introduction of new treatment for hepatitis C during the course of the study.
- •People who are at high risk of suicide.
- •Women who are pregnant or breastfeeding.
- •Participant is acutely ill with COVID-19 infection.
- •Use of prohibited medication (e.g. rifampicin).
- •Coagulopathy or use of anticoagulants which would preclude IM injections.
- •Any pre-existing physical or mental condition (including substance use disorder) which, in the opinion of the Investigator, may interfere with the participant’s ability to comply with the dosing schedule or which may compromise the safety of the participant.
研究者
相似试验
招募中
Unknown
Pre-Exposure Prophylaxis (PrEP) Implementation study of long-acting injectable cabotegravir (CAB-LA)RBR-8s3qz5sInstituto Nacional de Infectologia Evandro Chagas - INI/Fiocruz
进行中（未招募）
1 期
Trial to study the use of injectable buprenorphine in patients who persist in using illicit heroin to find an acceptable dose that could help reduce the use of illicit heroiAddiction to illicit heroinMedDRA version: 18.1Level: LLTClassification code 10019935Term: Heroin addictionSystem Organ Class: 100000004873MedDRA version: 18.1Level: LLTClassification code 10001127Term: Addiction to drugsSystem Organ Class: 100000004873EUCTR2011-001088-28-GBSouth London and Maudsley NHS Foundation Trust10
已完成
2 期
Assessing the safety and feasibility of depot buprenorphine in NSW custodial settingsOpioid use disorderMental Health - AddictionACTRN12618000942257SW Ministry of Health129
招募中
4 期
TOXSIALO-TRIAL : Evaluation of the long-term efficacy of the injection of botulinum toxin A into the salivary glands versus scopolamine patches in the treatment of drooling in children over 4 years old with cerebral palsy.2024-512160-58-00Hospices Civils De Lyon132
进行中（未招募）
不适用
ear Ifrared imaging of peritoneal metastasis of colon cancer origine.EUCTR2013-000653-42-BEJules Bordet Institute